WCG acquires pharmacovigilance firm Vigilare

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/oatawa)
(Image: iStock/oatawa)

Related tags Drug safety Pharmacology

WIRB Copernicus Group (WCG) has expanded its portfolio of companies to include the pharmacovigilance and drug safety solution provider Vigilare International.

The clinical services organization (CSO) has acquired Conshohocken, PA-based Vigilare International, which provides pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry.

Following the transaction – financial details of which were not disclosed – Vigilare will continue to operate as an independent service organization.

WCG will provide Vigilare access to capital, clinical and regulatory expertise, and corporate support, according to the company.

Craig Sowell, chief marketing officer at WCG told us the company seeks to partner with companies that share "the vision of increasing efficiencies within the clinical trial process.​"

WCG recognized Vigilare as a company with a similar mission and vision, he said.

"The Vigilare approach to providing end-to-end drug safety and pharmacovigilance services to the biopharmaceutical and biotech industry is a natural fit with WCG​," added Sowell.

WCG has made several other acquisitions in 2017, including the global patient recruitment, enrollment, and retention firm, ThreeWire​, as well as MedAvante and ProPhase​. In August, the company also acquired Patient Genesis’ ConsentNow​ electronic consent (eConsent) technology, which joined WCG’s platform of technology-enabled services.

Related news

Show more

Related products

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more